Highlighting advanced regenerative medicine technology by exhibiting 3D bioprinters and AI organ regeneration platforms.
ROKIT Genomics introduces customized single-cell and spatial transcriptomics analysis solutions for regenerative medicine and new drug development.
Supporting the entire process from consulting to integrated data analysis... Expanding cooperation with domestic and international pharmaceutical and bio companies.

ROKIT Healthcare (KOSDAQ: 376900, CEO You Seok-hwan), an AI hyper-personalized organ regeneration platform enterprise, and its subsidiary ROKIT Genomics, a precision omics analysis company, announced that they will participate in 'BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026)', held at COEX in Seoul from the 28th to the 30th.

BIX 2026 is a premier business conference where domestic and international bio-pharmaceutical companies and research institutions participate. It is an event that supports technological exchange and business-to-business cooperation through exhibitions, presentation sessions, and in-person partnering.

At this event, ROKIT Healthcare will focus on exhibiting its core technologies, the 3D bioprinter and AI organ regeneration platform, to promote its achievements in the field of advanced regenerative medicine.

ROKIT Genomics will introduce its single-cell and spatial transcriptomics analysis services utilized in bio-pharmaceutical research and development, and plans to conduct consultations for companies and research institutions requiring professional experimental and data analysis support.

ROKIT Genomics is a specialized analysis company focusing on the Single-cell RNA Sequencing field, having accumulated years of know-how in experiments and data analysis through various project execution experiences. Single-cell RNA sequencing is a technology that verifies gene expression characteristics at the individual cell level. Because it can analyze the composition, unique characteristics, and state changes of cell populations, it is widely utilized in life science and medical research, including regenerative medicine and new drug development.

Last year, the company officially launched its Spatial Transcriptomics analysis service, expanding its scope of analysis services. Spatial transcriptomics is a technology that simultaneously analyzes location information and gene expression patterns within a tissue. By analyzing the characteristics and spatial distribution of each cell type together, it can be utilized in research to comprehensively understand the tissue microenvironment and intercellular interactions.

In particular, based on its accumulated experience in experiments and data analysis, ROKIT Genomics holds a strong advantage in proposing analysis strategies tailored to the type and condition of the specimen and the research purpose. The company provides integrated support for the entire process, from project consulting and sample preprocessing to Next-Generation Sequencing (NGS) and bioinformatics analysis, while offering professional technical support through researcher-customized analysis and close communication.

A representative of ROKIT Healthcare stated, "Since the appropriate experimental methods and analysis strategies for single-cell analysis vary depending on the research purpose and specimen characteristics, accumulated analysis experience and professional academic support are crucial." They added, "Through BIX 2026, we will introduce ROKIT Genomics' analysis solutions to companies in the bio-pharmaceutical sector and expand opportunities for cooperation as a professional partner necessary for R&D projects."